During Senate confirmation proceedings, Dr. Heidi Overton, Trump's nominee for FDA leadership, demonstrated cautious positioning on two controversial policy areas. The hearing revealed strategic evasion of direct questioning regarding vaccine policy and reproductive health regulations. Senators sought clarity on Overton's stance toward pharmaceutical oversight and healthcare decisions, yet she maintained ambiguous responses. This confirmation process underscores growing tensions between executive health priorities and legislative scrutiny over critical FDA functions affecting millions of Americans.

Summary auto-generated by AI from the original publisher's content. Editorial standards.